Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Total Non-Current Liabilities (2018 - 2025)

Historic Total Non-Current Liabilities for Sangamo Therapeutics (SGMO) over the last 10 years, with Q3 2025 value amounting to $81.4 million.

  • Sangamo Therapeutics' Total Non-Current Liabilities rose 1486.15% to $81.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.4 million, marking a year-over-year increase of 1486.15%. This contributed to the annual value of $77.9 million for FY2024, which is 407.9% down from last year.
  • As of Q3 2025, Sangamo Therapeutics' Total Non-Current Liabilities stood at $81.4 million, which was up 1486.15% from $77.0 million recorded in Q2 2025.
  • Sangamo Therapeutics' 5-year Total Non-Current Liabilities high stood at $400.4 million for Q1 2021, and its period low was $68.1 million during Q2 2024.
  • Its 5-year average for Total Non-Current Liabilities is $186.2 million, with a median of $90.2 million in 2023.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first soared by 11765.83% in 2021, then tumbled by 7055.64% in 2023.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Total Non-Current Liabilities stood at $345.4 million in 2021, then fell by 22.88% to $266.3 million in 2022, then plummeted by 69.5% to $81.2 million in 2023, then fell by 4.08% to $77.9 million in 2024, then rose by 4.48% to $81.4 million in 2025.
  • Its Total Non-Current Liabilities was $81.4 million in Q3 2025, compared to $77.0 million in Q2 2025 and $80.3 million in Q1 2025.